Ascentage Pharma Group International ADR

Ascentage Pharma Group International ADR represents an interest in Ascentage Pharma Group International, a global biopharmaceutical company headquartered in Suzhou, China, with key operations also in Rockville, Maryland. The company focuses on discovering, developing, and commercializing novel small-molecule therapies that target protein-protein interactions to restore apoptosis, or programmed cell death, primarily in cancers, chronic hepatitis B, and certain age-related diseases. Its core activities center on hematological malignancies such as leukemia and lymphoma, where it is advancing differentiated drug candidates including Bcl-2 and dual Bcl-2/Bcl-xL inhibitors, MDM2-p53 and IAP pathway modulators, and next-generation kinase inhibitors. Ascentage Pharma Group International is a commercial-stage company, with its lead product, olverembatinib, approved and marketed in China, complemented by a broader pipeline under active clinical development across China, the United States, Australia, and Europe. In the global healthcare market, the asset provides exposure to innovative oncology and antiviral therapeutics developed through a proprietary research and development platform and strategic partnerships.